Consun Pharmaceutical Group Limited (HKG:1681)

Market Cap	12.66B -3.1%
Revenue (ttm)	4.19B +11.2%
Net Income	1.36B +16.5%
EPS	1.59 +17.2%
Shares Out	839.05M
PE Ratio	9.47
Forward PE	9.23
Dividend	0.80 (5.30%)
Ex-Dividend Date	Sep 8, 2026

Volume	1,699,000
Open	15.72
Previous Close	15.72
Day's Range	15.06 - 15.72
52-Week Range	12.31 - 19.49
Beta	0.43
Analysts	Buy
Price Target	22.65 (+50.1%)
Est. Earnings	Nov 26, 2026

About HKG:1681

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiol...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 2,847
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1681

Financial Performance

In 2025, HKG:1681's revenue was 3.42 billion, an increase of 15.17% compared to the previous year's 2.97 billion. Earnings were 1.08 billion, an increase of 18.41%.

Financial numbers in CNY

Analyst Summary

According to 3 analysts, the average rating for 1681 stock is "Buy." The 12-month stock price target is $22.65, which is an increase of 50.10% from the latest price.

Price Target

$22.65

(50.10% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error